Mediwound announces positive initial data from its u.s. phase i/ii study of mw005 for the treatment of basal cell carcinoma

Mw005 shown to be safe and well-tolerated target lesions clearance data provides clinical efficacy proof-of-concept
MDWD Ratings Summary
MDWD Quant Ranking